drugset / Trial / NCT05354050
Pharmacokinetic Study of DARE-BV1
NaSingle-groupOpen-labelTreatment
Summary
Single-Center, Phase 1, Single-dose PK study of DARE-BV1 (2% clindamycin phosphate vaginal gel, 100mg) under development for the treatment of bacterial vaginosis (BV).
Timeline
- Start
- 2020-11-03
- Primary completion
- 2020-11-18
- Completion
- 2020-12-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clindamycin | Unknown | 100 mg | Other |